abexxa

News

Boehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area in the space of a year.

News

Reports are emerging that the national priority voucher scheme launched by former FDA chief Marty Makary may be heading for the scrap heap.

Sales & Marketing

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.